Clinical Trial: EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV(R)) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19

U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT04822818) titled 'EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV(R)) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19' on March 25.

Brief Summary: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the most frequent complications of the COVID-19 pandemic. In these conditions, hypoxemia may result from : i) a pulmonary vascular dilatation resulting from an impaired hypoxic pulmonary vasoconstriction and leading to ventilation-perfusion mismatching within the lungs and ii) thrombosis-mediated perfusion defects. Pulmonary vascular dilation might be due to a relative failure of the physiological acute hypoxic pulmonary vasoconstriction, i...